Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I clinical pharmacology study of SJP-0125

Trial Profile

A phase I clinical pharmacology study of SJP-0125

Phase of Trial: Phase I

Latest Information Update: 19 Feb 2019

At a glance

  • Drugs SJP-0125 (Primary) ; Brimonidine; Brinzolamide
  • Indications Ocular hypertension; Open-angle glaucoma
  • Focus Pharmacokinetics
  • Sponsors Senju Pharmaceutical
  • Most Recent Events

    • 14 Feb 2019 Status changed from not yet recruiting to completed.
    • 15 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top